Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price target raised by equities research analysts at Canaccord Genuity Group from $64.00 to $98.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective suggests a potential upside of 21.91% from the stock’s current price.

Other analysts also recently issued research reports about the stock. The Goldman Sachs Group boosted their price objective on shares of Kiniksa Pharmaceuticals International from $60.00 to $75.00 and gave the company a “buy” rating in a report on Thursday, July 23rd. Wells Fargo & Company raised their price objective on Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Wedbush increased their target price on Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the company an “outperform” rating in a research report on Wednesday. Jefferies Financial Group boosted their price objective on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a research note on Tuesday, April 28th. Finally, Citigroup raised their price target on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, Kiniksa Pharmaceuticals International presently has a consensus rating of “Buy” and an average target price of $82.43.

Kiniksa Pharmaceuticals International Trading Up 1.2%

Shares of KNSA traded up $0.95 during midday trading on Wednesday, reaching $80.39. The stock had a trading volume of 857,880 shares, compared to its average volume of 729,710. Kiniksa Pharmaceuticals International has a one year low of $29.66 and a one year high of $82.94. The firm has a market cap of $6.18 billion, a PE ratio of 89.52 and a beta of 0.07. The firm has a 50 day simple moving average of $57.59 and a 200-day simple moving average of $50.44.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.30. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The business had revenue of $243.60 million for the quarter, compared to analyst estimates of $226.49 million. As a group, research analysts forecast that Kiniksa Pharmaceuticals International will post 1.25 EPS for the current fiscal year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, insider John F. Paolini sold 58,424 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $53.71, for a total transaction of $3,137,953.04. Following the transaction, the insider owned 65,623 shares of the company’s stock, valued at $3,524,611.33. This trade represents a 47.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 48,565 shares of the stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $54.02, for a total value of $2,623,481.30. Following the sale, the chief executive officer directly owned 48,565 shares of the company’s stock, valued at $2,623,481.30. The trade was a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 109,130 shares of company stock valued at $5,877,070 in the last quarter. 51.98% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC grew its position in Kiniksa Pharmaceuticals International by 140.4% during the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after buying an additional 532 shares in the last quarter. Osaic Holdings Inc. bought a new stake in Kiniksa Pharmaceuticals International in the second quarter valued at approximately $31,000. KBC Group NV purchased a new stake in Kiniksa Pharmaceuticals International during the 1st quarter valued at $34,000. Smartleaf Asset Management LLC bought a new stake in shares of Kiniksa Pharmaceuticals International in the fourth quarter worth about $36,000. Finally, Nano Cap New Millennium Growth Fund L P purchased a new position in shares of Kiniksa Pharmaceuticals International during the fourth quarter valued at approximately $41,000. 53.95% of the stock is currently owned by institutional investors.

Kiniksa Pharmaceuticals International News Roundup

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Analysts raised their price targets. Wedbush lifted its target from $72 to $99 and maintained an “outperform” rating, while Citigroup raised its target from $60 to $100 and upgraded or maintained a “buy” rating. The new targets imply roughly 23%–24% potential upside from recent trading levels. Benzinga analyst ratings
• Positive Sentiment: Revenue guidance was increased. Kiniksa now expects 2026 revenue of $980 million to $995 million, above the approximately $940 million consensus estimate. ARCALYST second-quarter net product revenue reached $243.6 million, up about 55% year over year and well ahead of expectations. Kiniksa second-quarter results
• Positive Sentiment: KPL-387 advanced toward pivotal testing. Phase 2 data showed rapid and sustained reductions in pain and inflammation, and the selected 300 mg monthly dose is now being evaluated in an enrolling Phase 3 trial for recurrent pericarditis. KPL-387 pipeline update
• Neutral Sentiment: Profitability was broadly in line. Quarterly EPS of $0.30 matched consensus, although it improved from $0.23 a year earlier; the main earnings catalyst was the substantial revenue beat rather than an EPS surprise. Kiniksa earnings report

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.